FDA MRD guidance in multiple myeloma: what BD teams should track
Decision brief
Answer first · skim in under a minute
The FDA has issued draft guidance on using MRD and complete response as endpoints in multiple myeloma trials. This plan frames what changed, why MRD matters for accelerated approval, and what BD teams and investors should watch next.
Key questions this brief answers
- What did FDA’s January 2026 MRD guidance cover?
- Does the guidance require MRD as an endpoint?
- What MRD threshold does FDA discuss?
Navigating FDA Expectations for Minimal Residual Disease (MRD) is now clearer after FDA’s January 2026 draft guidance on using MRD and complete response as primary endpoints to support accelerated approval in multiple myeloma. Sponsors should align assay thresholds, timing, and confirmatory plans before the next protocol submission.
Contents11 sections
Key Takeaways
- FDA posted January 2026 draft guidance on MRD and complete response endpoints for accelerated approval in multiple myeloma (docket FDA-2025-D-2616).
- MRD negativity is defined in patients who achieved CR (including stringent CR), assessed in bone marrow by flow cytometry or sequencing methods.
- ODAC members on 12 April 2024 unanimously agreed it is acceptable to use MRD as an accelerated-approval endpoint in multiple myeloma.
- Guidance recommends MRD negativity at a threshold of at least 1 in 10^5 residual tumor cells unless an alternate threshold is justified.
What does the January 2026 FDA draft say about MRD?
FDA’s draft guidance, Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval, advises sponsors on using MRD and complete response (CR) as primary endpoints to support accelerated approval for multiple myeloma drugs and biologics.
The FDA guidance page defines the MRD endpoint as MRD negativity rate in bone marrow by flow cytometry- or sequencing-based methods in patients who achieved CR; CR includes stringent CR. Download the draft PDF at fda.gov/media/190647.
Why did FDA open this pathway for MRD?
At the Oncologic Drugs Advisory Committee meeting on 12 April 2024, members unanimously agreed that available evidence supports using MRD as an accelerated-approval endpoint in multiple myeloma. Meta-analyses discussed at ODAC linked deeper responses to longer-term outcomes such as progression-free and overall survival.
FDA also notes CR itself is a recognized prognostic biomarker. The draft states CR rate can support accelerated approval under principles similar to those for MRD. See related US oncology coverage in our US oncology category.
How should sponsors design MRD-based trials?
Protocols should specify how CR is confirmed before MRD assessment, the assay platform, and the analysis timepoint. FDA says MRD negativity should be assessed at a threshold of at least 1 residual tumor cell in 10^5 cells unless an alternate threshold is appropriately justified.
Randomized trials are preferred when isolating combination-regimen effects on MRD negativity. Single-arm designs need carefully justified target MRD rates. Teams following broader FDA guidance updates should keep MRD statistical plans synchronized with labeling strategy.
What does this mean for BD and investors?
MRD-negative CR can shorten the path to an accelerated-approval filing if confirmatory endpoints and assay validation are locked early. Deal models should stress-test durability requirements and whether a single pivotal trial can support both accelerated and traditional approval.
CAR T programs may need extra caution: ODAC meta-analyses did not fully cover CAR T contexts in the same way as conventional regimens. Compare asset timelines against peers tracked in multiple myeloma disease coverage.
What open questions remain for sponsors?
Sponsors still need FDA alignment on maintenance-setting MRD claims, durability metrics, and how sustained MRD negativity might later support traditional approval. The draft is guidance, not a binding checklist.
Comment via docket FDA-2025-D-2616 if assay logistics or disease-setting nuances are unclear. Pair regulatory reading with primary literature such as PMC11707509 on MRD methodology.
How should medical affairs message MRD endpoints?
Keep external communication limited to trial design context until approval. Distinguish prognostic biomarker language from validated surrogate claims in promotional settings.
Train investigators on sample timing windows around CR confirmation so site practice matches the protocol’s MRD analysis population.
How should assay vendors and CROs respond?
Assay vendors should publish analytical validation packages that map to the draft’s 10^5 sensitivity floor and to flow versus next-generation sequencing platforms. CROs need specimen logistics that preserve bone marrow quality inside the protocol’s CR-confirmation window.
Central lab manuals should define regenerating samples when MRD is indeterminate and should pre-specify how missing MRD assessments are handled in the primary analysis population. Early FDA Type C dialogue remains useful when sponsors propose alternate thresholds.
What filing strategy trade-offs remain after the draft?
Accelerated approval on MRD-negative CR can bring earlier revenue, but confirmatory progression-free or overall survival commitments still bind the program. Investors should model label narrowing if confirmatory results underperform the MRD signal.
Competitive diligence should compare time-to-MRD readout against peers using older overall response endpoints. In crowded multiple myeloma classes, a clearer FDA endpoint path can compress development calendars by one to two readout cycles when enrollment is already strong.
Frequently Asked Questions
What did FDA’s January 2026 MRD guidance cover?
It provides recommendations on using minimal residual disease and complete response as primary endpoints to support accelerated approval in multiple myeloma trials.
Does the guidance require MRD as an endpoint?
No. It explains when and how sponsors may use MRD negativity rate and CR rate to support accelerated approval; it does not mandate MRD for every myeloma program.
What MRD threshold does FDA discuss?
FDA states MRD negativity should be assessed at a threshold of at least 1 in 10^5 residual tumor cells, with alternate thresholds needing appropriate justification.
